Suppr超能文献

通过逆转录聚合酶链反应检测外周血中细胞角蛋白20的结肠癌细胞。

Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20.

作者信息

Wyld D K, Selby P, Perren T J, Jonas S K, Allen-Mersh T G, Wheeldon J, Burchill S A

机构信息

ICRF Cancer Medicine Research Unit, St. James's University Hospital, Leeds, UK.

出版信息

Int J Cancer. 1998 Jun 19;79(3):288-93. doi: 10.1002/(sici)1097-0215(19980619)79:3<288::aid-ijc14>3.0.co;2-4.

Abstract

The staging of colorectal cancer currently depends on pathological examination of the surgical specimen and regional lymph nodes, accompanied by imaging tests such as computed tomography (CT) scanning. However, alternative molecular methods to detect circulating tumour cells in blood or bone marrow may provide additional information about the extent of disease and prognosis. We have previously reported the development of a reverse-transcriptase polymerase chain reaction (RT-PCR) for cytokeratin 20 (CK 20) mRNA to detect circulating epithelial tumour cells. In this study, we report on the application of this method for detecting circulating tumour cells in patients with colorectal cancer. Using this method, CK 20 mRNA was detected in 8/8 human colorectal cancer cell lines, in 8/9 biopsies from primary colorectal tumours and in 9/10 biopsies of liver metastasis in patients with metastatic colorectal cancer, suggesting that CK 20 may be a useful target for the detection of circulating tumour cells in this patient group. In spiking experiments, 10 cells were consistently identified in 2 ml of whole blood (1 x 10(6)-1 x 10(7) mononuclear cells). In 12/25 (48%) peripheral blood samples from patients with known metastatic colorectal cancer, CK 20 mRNA was detected. However, there was no correlation between the detection of CK 20 mRNA in the peripheral blood and disease progression and survival in this group of patients. CK 20 mRNA was detected in 1/12 normal blood samples, which raises questions about the absolute specificity of CK 20 expression.

摘要

目前,结直肠癌的分期取决于手术标本及区域淋巴结的病理检查,并辅以计算机断层扫描(CT)等影像学检查。然而,检测血液或骨髓中循环肿瘤细胞的其他分子方法可能会提供有关疾病范围和预后的更多信息。我们之前报道了一种用于检测细胞角蛋白20(CK 20)mRNA的逆转录聚合酶链反应(RT-PCR),以检测循环上皮肿瘤细胞。在本研究中,我们报告了该方法在检测结直肠癌患者循环肿瘤细胞中的应用。使用该方法,在8/8个人类结直肠癌细胞系、9例原发性结直肠癌活检组织中的8例以及10例转移性结直肠癌患者肝转移活检组织中的9例中检测到了CK 20 mRNA,这表明CK 20可能是检测该患者群体循环肿瘤细胞的一个有用靶点。在加样实验中,在2 ml全血(1×10⁶ - 1×10⁷个单核细胞)中始终能检测到10个细胞。在25例已知有转移性结直肠癌患者的外周血样本中,12例(48%)检测到了CK 20 mRNA。然而,该组患者外周血中CK 20 mRNA的检测与疾病进展及生存之间并无相关性。在12例正常血液样本中的1例中检测到了CK 20 mRNA,这引发了关于CK 20表达绝对特异性 的疑问。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验